FibroGen, Inc.
FGEN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,076 | $1,348 | $2,739 | -$123,256 |
| % Growth | -20.2% | -50.8% | 102.2% | – |
| Cost of Goods Sold | -$58 | $85 | $252 | -$20,666 |
| Gross Profit | $1,134 | $1,263 | $2,487 | -$102,590 |
| % Margin | 105.4% | 93.7% | 90.8% | 83.2% |
| R&D Expenses | $1,209 | $5,865 | $9,175 | $1,486 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,295 | $7,057 | $8,106 | -$13,320 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $41 | $393 | $126 | $900 |
| Operating Expenses | $6,545 | $13,315 | $17,407 | -$10,934 |
| Operating Income | -$5,411 | -$12,052 | -$14,920 | -$91,656 |
| % Margin | -502.9% | -894.1% | -544.7% | 74.4% |
| Other Income/Exp. Net | -$7,735 | -$1,723 | -$1,844 | $4,067 |
| Pre-Tax Income | -$13,146 | -$13,775 | -$16,764 | -$87,589 |
| Tax Expense | $0 | -$92 | $2 | -$52 |
| Net Income | $200,636 | -$7,603 | $4,639 | $17,982 |
| % Margin | 18,646.5% | -564% | 169.4% | -14.6% |
| EPS | 49.61 | -1.88 | 0.05 | 4.5 |
| % Growth | 2,738.8% | -3,860% | -98.9% | – |
| EPS Diluted | 49.61 | -1.88 | 0.05 | 4.5 |
| Weighted Avg Shares Out | 4,044 | 4,042 | 100,954 | 4,033 |
| Weighted Avg Shares Out Dil | 4,044 | 4,042 | 100,954 | 4,033 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $286 | $413 | $204 |
| Interest Expense | $2,083 | $2,009 | $2,257 | $0 |
| Depreciation & Amortization | $192 | $221 | $327 | $352 |
| EBITDA | -$10,871 | -$11,545 | -$14,180 | -$91,100 |
| % Margin | -1,010.3% | -856.5% | -517.7% | 73.9% |